Reduced functional independence and multimorbidity increases the risk of severe infection among older patients with Omicron: a multicenter retrospective cohort study.

ingentiumby ingentium

In Clinical Literature.

Publication date: Feb 06, 2025

Multimorbidity and physical function in older adults have been identified as associated with coronavirus disease 2019 (COVID-19) outcomes. This study aimed to investigate whether multimorbidity affects the association of impaired functional independence (FI) with critical COVID-19 among older inpatients during the peak of Omicron infection in China. This is a multicentre, retrospective cohort study in northeastern China. Patients aged ≥ 60 years, who were diagnosed with COVID-19 at the time of admission or during hospitalisation. The Barthel index was used to assess FI. Patients were classified into independent, mildly dependent, moderately dependent, and severely dependent groups. Disease severity was classified as critical, severe, and non-severe and combined into severe or critical and non-severe. Binary logistic regression analysis was used to investigate any correlation between FI and disease severity. Patients were further stratified by presence or absence of multimorbidity. In this study, of 1598 patients, 530 (33. 17%) developed severe or critical infections during the entire hospital stay. Patients with severe dependency had 7. 39 times (95% CI: [4. 60, 12. 15]) higher risk of serious or critical infections than those without dependency. An interaction was noted between reduced FI and multimorbidity (p for interaction 

Open Access PDF

Concepts Keywords
Aged60 Barthel index
China Functional independence
Coronavirus Multimorbidity
Hospitalisation Older patients
Severe Omicron

Semantics

Type Source Name
disease MESH functional independence
disease MESH infection
disease MESH coronavirus disease 2019
disease MESH Long Covid
pathway REACTOME Reproduction
disease MESH Comorbidity
disease MESH chronic diseases
drug DRUGBANK Trestolone
disease MESH morbidity
disease IDO acute infection
disease MESH emergency
pathway REACTOME Translation
disease IDO nucleic acid
drug DRUGBANK Methionine
disease IDO history
disease IDO blood
drug DRUGBANK Human Serum Albumin
disease MESH hypertension
disease MESH stroke
disease MESH heart disease
disease MESH malignancy
disease MESH lung disease
disease MESH liver disease
disease MESH kidney disease
disease MESH gastrointestinal disease
disease MESH psychiatric disorders
disease MESH arthritis
disease MESH rheumatism
disease MESH asthma
pathway KEGG Asthma
disease MESH glaucoma
disease MESH cataracts
disease MESH syndrome
disease MESH sepsis
disease MESH septic shock
drug DRUGBANK Oxygen
drug DRUGBANK Medical air
disease MESH pneumonia
drug DRUGBANK Esomeprazole
disease MESH death
disease MESH inflammation
disease MESH frailty
disease MESH lung injury
disease MESH hypoxemic respiratory failure
disease IDO susceptibility
drug DRUGBANK Indoleacetic acid
disease MESH infectious diseases
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Coenzyme M
disease MESH Brain Disorders
pathway REACTOME Metabolism
drug DRUGBANK Guanosine
disease MESH depression
disease MESH anxiety
drug DRUGBANK Rasagiline
drug DRUGBANK Metoclopramide
disease MESH heart failure
pathway REACTOME Cellular Senescence
disease IDO cell
disease MESH multiple chronic conditions
disease MESH urological diseases
disease MESH benign prostatic hyperplasia

Original Article

(Visited 2 times, 1 visits today)